Trial Profile
A Phase 1b Study to Evaluate the Safety of PRV-300 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 May 2019
Price :
$35
*
At a glance
- Drugs JNJ 42915925 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Acronyms PULSE
- Sponsors Provention Bio
- 08 May 2019 Results presented in a Provention Bio media release.
- 11 Mar 2019 Status changed from active, no longer recruiting to completed.
- 23 Oct 2018 According to Provention Bio a media release, top-line data from PULSE is expected in the second quarter of 2019.